PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION - DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTICENTER STUDY

被引:80
作者
BREVETTI, G [1 ]
PERNA, S [1 ]
SABBA, C [1 ]
MARTONE, VD [1 ]
CONDORELLI, M [1 ]
机构
[1] UNIV BARI, DEPT MED, BARI, ITALY
关键词
D O I
10.1016/0735-1097(95)00344-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The aim of this double-blind, placebo-controlled, dose titration, multicenter trial was to assess the efficacy and safety of propionyl-L-carnitine in intermittent claudication. Background. Human and animal studies indicate that propionyl-L-carnitine increases carnitine content and improves energy metabolism in the ischemic skeletal muscle. Methods. After a 2-week preliminary period to assess maximal walking distance, 245 patients were randomly assigned to receive propionyl-L-carnitine (n = 118) or placebo (n = 127). The initial oral dose of 500 mg twice daily was increased at 2-month intervals to 2 g/day and then to 3 g/day in patients showing improvement in treadmill performance <30% over baseline. Efficacy analysis was conducted for the 214 patients who completed the 24 weeks of treatment by comparing the effect of placebo and propionyl-L-carnitine on day 180. Results. Analysis of variance showed a significant improvement of 73 +/- 9% (mean +/- SE) in maximal walking distance with propionyl-L-carnitine (n = 99) compared with 46 +/- 6% for placebo (n = 115, p = 0.03). For distance walked at onset of claudication, propionyl-L-carnitine showed about double the improvement of placebo; however, the difference was not statistically significant. There were no changes in electrocardiographic and routine biochemical and hematologic tests that would indicate an adverse effect of propionyl-L-carnitine. Adverse events requiring drug discontinuation (II in the propionyl-L-carnitine group, 3 in the placebo group) were unrelated to study medication. The dose titration design of the study also provided information on the dose-response relation. Slightly less than 67% of patients were expected to improve their maximal walking distance by at least 30%, assuming 2 g/day of propionyl-L-carnitine (95% confidence interval 0.51 to 0.70). The response rate during the entire titration course was significantly in favor of propionyl-L-carnitine compared with placebo. Conclusions. Although the precise mode of therapeutic action requires clarification, propionyl-L-carnitine, at a dose of 1 to 2 g/day, appears to be effective and well tolerated, with minimal adverse effects.
引用
收藏
页码:1411 / 1416
页数:6
相关论文
共 36 条
  • [11] EFFECT OF KETANSERIN IN THE TREATMENT OF PATIENTS WITH INTERMITTENT CLAUDICATION - RESULTS FROM 13 PLACEBO-CONTROLLED PARALLEL GROUP STUDIES
    CLEMENT, DL
    DUPREZ, D
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1987, 10 : S89 - S95
  • [12] EFFECT OF PROPIONYL-L-CARNITINE IN A RAT MODEL OF PERIPHERAL ARTERIOPATHY - A FUNCTIONAL, HISTOLOGIC, AND NMR SPECTROSCOPIC STUDY
    CORSICO, N
    NARDONE, A
    LUCREZIOTTI, MR
    SPAGNOLI, LG
    PESCE, D
    AURELI, T
    DICOCCO, ME
    MICCHELI, A
    CONTI, F
    MARTELLI, EA
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 1993, 7 (02) : 241 - 251
  • [13] PYRUVATE-CARBOXYLASE AND PROPIONYL-COA CARBOXYLASE AS ANAPLEROTIC ENZYMES IN SKELETAL-MUSCLE MITOCHONDRIA
    DAVIS, EJ
    SPYDEVOLD, O
    BREMER, J
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1980, 110 (01): : 255 - 262
  • [14] Denton R M, 1979, Essays Biochem, V15, P37
  • [15] DETTORI AG, 1989, ANGIOLOGY, V40, P237, DOI 10.1177/000331978904000401
  • [16] DOES OXPENTIFYLLINE (TRENTAL) HAVE A PLACE IN THE TREATMENT OF INTERMITTENT CLAUDICATION
    DONALDSON, DR
    HALL, TJ
    KESTER, RC
    RAMSDEN, CW
    WIGGINS, PA
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 1984, 9 (01) : 35 - 40
  • [17] DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50
  • [18] EKROTH R, 1978, SURGERY, V84, P640
  • [19] ENGEL AG, 1980, CARNITINE BIOSYNTHES, P271
  • [20] INTERMITTENT CLAUDICATION - A DOUBLE-BLIND CROSSOVER TRIAL OF PENTOXIFYLLINE
    GALLUS, AS
    GLEADOW, F
    DUPONT, P
    WALSH, J
    MORLEY, AA
    WENZEL, A
    ALDERMAN, M
    CHIVERS, D
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1985, 15 (04): : 402 - 409